Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;1.006;73;1.079;
%Companies according to biotechnology used: Genetic code;34;55;35;
%Companies according to biotechnology used: Functional units;44;53;44;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;25;47;26;
%Companies according to biotechnology used: Bioprocesses;48;64;49;
%Companies according to biotechnology used: Sub-cellular organisms;8;15;8;
%Companies according to biotechnology used: Bio-computing;23;23;23;
%Companies according to biotechnology used: Nanobiotechnology;15;12;15;
%Companies according to biotechnology used: Other;12;11;12;
Companies in which biotechnology activities are: Main and/or exclusive;503;16;519;
Companies in which biotechnology activities are: A secondary line of business;158;21;179;
Companies in which biotechnology activities are: A tool necessary for production;345;36;381;
%Company by field(s) of ultimate application of biotechnology use: Human Health;47;51;48;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;22;4;21;
%Company by field(s) of ultimate application of biotechnology use: Food products;33;34;33;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;21;22;
%Company by field(s) of ultimate application of biotechnology use: Environment;17;21;17;
%Company by field(s) of ultimate application of biotechnology use: Industry;15;8;15;
Personnel in R&D in biotechnology (no. of persons);7.556;2.239;9.795;
Personnel in R&D in biotechnology (no. of persons): Researchers;4.379;1.194;5.573;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3.177;1.045;4.222;
Personnel in R&D in biotechnology (no. of persons): women;4.032;1.267;5.298;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.279;646;2.925;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1.752;621;2.373;
Personnel in R&D in biotechnology (FTE);5.209,9;1.618,7;6.828,6;
Personnel in R&D in biotechnology (FTE): Researchers;3.191,6;914,9;4.106,5;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.018,3;703,8;2.722,1;
Personnel in R&D in biotechnology (FTE): women;2.872,2;939,6;3.811,7;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1.682,6;508,1;2.190,7;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.189,5;431,5;1.621;
Internal expenditure on R&D (thousands of euros);402.391;131.434;533.826;
1) By nature of the expense: Current expenses;365.997;126.959;492.955;
1.1) Remuneration to researchers;153.274;50.166;203.439;
1.2) Remuneration to technicians and assistants;67.291;29.559;96.850;
1.3) Other current expenses;145.432;47.234;192.666;
2) By nature of the expense: Capital expenses;36.395;4.476;40.870;
2.1) Land and buildings;6.634;888;7.521;
2.2) Equipment and instruments;28.690;3.388;32.078;
2.3) Acquisition of specific R&D software;1.071;200;1.270;
1) By origin of the funds: National funds;329.975;102.895;432.869;
1.1) Own funds;239.006;80.039;319.046;
1.2) From companies;30.715;8.538;39.253;
1.3) Public Administration funds;57.667;12.396;70.063;
1.4) From Universities;156;0;156;
1.5) From non profit private institutions;2.431;1.921;4.351;
1) By origin of the funds: Foreign funds;72.416;28.540;100.956;
2.1) From EU programmes;18.073;1.998;20.070;
2.2) Other foreign funds;54.344;26.542;80.886;
Purchase of R&D services in biotechnology (thousands of euros);76.625;62.000;138.625;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;64.575;36.539;101.114;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;12.050;25.462;37.512;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;48;25;46;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;10;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;12;12;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;17;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;19;18;19;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;20;12;19;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;18;21;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;36;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;50;44;49;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;11;19;
% Companies that have requested biotechnology patents in Biotechnology;15;22;15;
Number of patents requested;397;69;466;
% Companies with income of an international origin related to biotechnological activities;25,3;20,5;24,9;
% Turnover representing income of an international origin related to biotechnological activities;4;0,7;0,9;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;49,5;81;71,3;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;50,5;19,1;28,7;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;76,2;99,2;92,2;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;7,8;.;2,4;
% Income of an international origin related with activities according to the classification: Operating source abroad;3,2;0,4;1,3;
% Income of an international origin related with activities according to the classification: Other;12,7;0,4;4,2;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute